secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001140361-25-007516
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech initiates VERSATILE-003 Phase 3 trial for Versamune HPV in head and neck cancer
--------------------------------------------------------------------------------

- Phase 3 trial VERSATILE-003 now open to patient enrollment for HPV16-positive head and neck cancer.
- Trial to enroll ~350 patients at 2:1 ratio; primary endpoint is overall survival.
- First-ever Phase 3 trial in HPV16-positive head and neck cancer.
- Versamune HPV already has FDA Fast Track designation based on Phase 2 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125007516/0001140361-25-007516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125007516/ef20045063_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-007516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer